fenofibrate has been researched along with Apolipoprotein B-100, Familial Defective in 72 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy and safety of coadministration of fenofibrate (NanoCrystal(R)) and ezetimibe in patients with type IIb dyslipidemia and the metabolic syndrome compared with administration of fenofibrate and ezetimibe alone (ClinicalTrials." | 9.14 | Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, ( Ansquer, JC; Bekaert, I; Guy, M; Hanefeld, M; Simon, A, 2009) |
| "To evaluate the effect of micronised fenofibrate on serum paraoxonase (PON) and lipoprotein levels in coronary heart disease patients with type IIb hyperlipidemia." | 7.72 | The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease. ( Balogh, Z; Boda, J; Harangi, M; Illyés, L; Kovács, P; Paragh, G; Seres, I; Szilvássy, Z, 2003) |
| "Fibrinogen in plasma was reduced from 3." | 5.29 | [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia]. ( Ceska, R; Haas, T; Kvasilová, M; Kvasnicka, J; Procházková, R; Sobra, J, 1996) |
| "To assess the efficacy and safety of coadministration of fenofibrate (NanoCrystal(R)) and ezetimibe in patients with type IIb dyslipidemia and the metabolic syndrome compared with administration of fenofibrate and ezetimibe alone (ClinicalTrials." | 5.14 | Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, ( Ansquer, JC; Bekaert, I; Guy, M; Hanefeld, M; Simon, A, 2009) |
| "To investigate the lipoprotein effect of fenofibrate in hypercholesterolemia or combined hyperlipidemia (types II A and II B hyperlipidemias, respectively), 240 patients were recruited and 227 randomized to a double-blind randomized trial lasting 24 weeks and 192 patients continued to participate in an open-label phase for another 24 weeks." | 5.06 | Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. ( Brown, WV; Dujovne, CA; Farquhar, JW; Feldman, EB; Goldberg, AC; Grundy, SM; Knopp, RH; Lasser, NL; Mellies, MJ; Palmer, RH, 1987) |
| "To evaluate the effect of micronised fenofibrate on serum paraoxonase (PON) and lipoprotein levels in coronary heart disease patients with type IIb hyperlipidemia." | 3.72 | The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease. ( Balogh, Z; Boda, J; Harangi, M; Illyés, L; Kovács, P; Paragh, G; Seres, I; Szilvássy, Z, 2003) |
| "Fenofibrate effect on plasma lipids and lipoproteins was studied in 23 patients with primary hyperlipoproteinemias (HLP): 12 with familial hypercholesterolemia (FH), 5 with combined HLP and 6 with Type III HLP." | 3.67 | Long term-effect of fenofibrate on lipoprotein level and composition in different types of genetic hyperlipidemias. ( Baggio, G; Ciuffetti, G; Crepaldi, G; Fellin, R; Gabelli, C; Gasparotto, A; Senin, U; Valerio, G, 1986) |
| "The atorvastatin regimen was marginally but not significantly better than simvastatin-fenofibrate in improving the LDL:HDL ratio, LDL:apoB and and apolipoprotein B:A1 ratios." | 2.69 | High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia. ( Crook, MA; Lumb, PJ; Semra, YK; Wierzbicki, AS, 1998) |
| "Simvastatin was associated with statistically significantly greater (p < or = 0." | 2.68 | Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. ( Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W, 1995) |
| " At the same time the pharmacokinetics was studied to check whether this new dosage schedule would give a therapeutic plasma levels of fenofibrate." | 2.66 | Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb. ( Balestreri, R; Bertolini, S; Carozzi, A; Cotta Ramusino, AM; Daga, A; Degl'Innocenti, ML; Elicio, N; Fusi, MG, 1988) |
| "Ciprofibrate has the benefit of a long half-life and may also be administered in the form of a single daily dose to patients suffering from major type II hyperlipoproteinaemia." | 2.66 | Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B. ( Bakir, R; Chanu, B; Djian, F; Goy-Loeper, J; Rouffy, J, 1985) |
| " Micronized fenofibrate, a new formulation chemically identical to the parent compound, has improved pharmacokinetic parameters which increase absorption, provide more stable plasma levels, and thus dosage can be decreased." | 2.39 | The fibrates in clinical practice: focus on micronised fenofibrate. ( Shepherd, J, 1994) |
| "Dysbetalipoproteinemia (dysb) and familial hypercholesterolemia (FH) are two genetic disorders giving rise to severe disturbances of lipid homeostasis and premature atherosclerosis." | 1.33 | Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia. ( Couture, P; Deshaies, Y; Gagné, C; Hogue, JC; Lamarche, B; Ruel, IL; Tremblay, AJ, 2006) |
| "In patients with type IIa or IIb dyslipidemia, TC decreased (-14." | 1.31 | Efficacy and tolerability of a "suprabioavailable" formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials. ( Callaghan, DJ; Ramjattan, BR; Theiss, U, 2002) |
| "Fibrinogen in plasma was reduced from 3." | 1.29 | [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia]. ( Ceska, R; Haas, T; Kvasilová, M; Kvasnicka, J; Procházková, R; Sobra, J, 1996) |
| "Twenty two patients with primary type II hyperlipoproteinemia (13 phenotype IIa and 9 phenotype IIb) were treated with fenofibrate 300 mg a day for 4-12 months." | 1.27 | Long-term effects of fenofibrate on serum lipids and on lipoprotein cholesterol in type II hyperlipoproteinemic patients. ( Bonfiglioli, D; Cabrini, E; Fasoli, A; Pogliaghi, I; Sommariva, D, 1984) |
| "In patients with heterozygous familial hypercholesterolemia (FH), bezafibrate (n = 5) and fenofibrate (n = 7) produced a similar significant reduction of total cholesterol, LDL-cholesterol, and triglycerides by 21, 23, and 32%, respectively." | 1.27 | Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate. ( Leiss, O; Meyer-Krahmer, K; von Bergmann, K, 1986) |
| "Fenofibrate was well tolerated, both clinically and biologically." | 1.26 | [One year fenofibrate treatment of type II primary hyperlipidaemia. Effects on lipoproteins and biological tolerance (author's transl)]. ( Debry, G; Drouin, P; Lambert, D; Méjean, L; Wülfert, E, 1980) |
| "Fenofibrate was well tolerated." | 1.26 | [Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)]. ( Gustafson, A; Micheli, H; Pometta, D, 1980) |
| "Fenofibrate was also found to normalize platelet aggregation in patients with type IIb HLP." | 1.26 | [Pharmacology of fenofibrate (author's transl)]. ( Kritchevsky, D, 1980) |
| "Eleven patients with hyperlipoproteinemia (HLP) type II A, were treated for 3 months with a new compound, a phenoxy-isobuturic acid derivative, procetofen, at a dosage of 100 mg t." | 1.26 | Treatment of hyperlipoproteinemia (HLP) type II A with a new phenoxy-isobuturic acid derivative, procetofen. ( Gustafson, A; Micheli, H; Pometta, D, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 43 (59.72) | 18.7374 |
| 1990's | 19 (26.39) | 18.2507 |
| 2000's | 9 (12.50) | 29.6817 |
| 2010's | 1 (1.39) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Page, MM | 1 |
| Ekinci, EI | 1 |
| Jones, RM | 1 |
| Angus, PW | 1 |
| Gow, PJ | 1 |
| O'Brien, RC | 1 |
| Ansquer, JC | 1 |
| Bekaert, I | 1 |
| Guy, M | 1 |
| Hanefeld, M | 1 |
| Simon, A | 1 |
| Ramjattan, BR | 1 |
| Callaghan, DJ | 1 |
| Theiss, U | 1 |
| Okopień, B | 5 |
| Cwalina, Ł | 1 |
| Haberka, M | 1 |
| Kowalski, J | 5 |
| Zieliński, M | 5 |
| Szwed, Z | 1 |
| Kalina, Z | 5 |
| Herman, ZS | 4 |
| Madej, A | 3 |
| Belowski, D | 1 |
| Paragh, G | 1 |
| Seres, I | 1 |
| Harangi, M | 1 |
| Balogh, Z | 1 |
| Illyés, L | 1 |
| Boda, J | 1 |
| Szilvássy, Z | 1 |
| Kovács, P | 1 |
| Tremblay, AJ | 1 |
| Lamarche, B | 1 |
| Ruel, IL | 1 |
| Hogue, JC | 1 |
| Deshaies, Y | 1 |
| Gagné, C | 1 |
| Couture, P | 1 |
| Christidis, DS | 1 |
| Liberopoulos, EN | 1 |
| Kakafika, AI | 1 |
| Miltiadous, GA | 1 |
| Cariolou, M | 1 |
| Ganotakis, ES | 1 |
| Mikhailidis, DP | 1 |
| Elisaf, MS | 1 |
| Kourimate, S | 1 |
| Le May, C | 1 |
| Langhi, C | 1 |
| Jarnoux, AL | 1 |
| Ouguerram, K | 1 |
| Zaïr, Y | 1 |
| Nguyen, P | 1 |
| Krempf, M | 1 |
| Cariou, B | 1 |
| Costet, P | 1 |
| Paoletti, R | 1 |
| Franceschini, G | 2 |
| Sirtori, CR | 2 |
| Sznajd, J | 1 |
| Magdoń, M | 1 |
| Idzior, B | 1 |
| Konarska, R | 1 |
| Malczewska, M | 1 |
| Czarnecka, H | 1 |
| Sznajderman, M | 2 |
| Sommariva, D | 3 |
| Bonfiglioli, D | 2 |
| Pogliaghi, I | 2 |
| Ottomano, C | 1 |
| Fasoli, A | 3 |
| Cabrini, E | 1 |
| Capurso, A | 1 |
| Mogavero, AM | 1 |
| Taverniti, R | 1 |
| Resta, F | 1 |
| Pace, L | 1 |
| Bonomo, L | 1 |
| Chicaud, P | 1 |
| Demange, J | 1 |
| Drouin, P | 7 |
| Debry, G | 6 |
| Gariot, P | 2 |
| Barrat, E | 2 |
| Mejean, L | 3 |
| Pointel, JP | 2 |
| Schwartzkopff, W | 2 |
| Luley, C | 2 |
| Scheffler, W | 2 |
| Lehmann-Leo, W | 1 |
| Schilling, A | 2 |
| Wegscheider, K | 1 |
| Lehtonen, A | 1 |
| Viikari, J | 1 |
| Lambert, D | 2 |
| Wülfert, E | 1 |
| Micheli, H | 2 |
| Pometta, D | 2 |
| Gustafson, A | 2 |
| Renaud, S | 2 |
| Dumont, E | 2 |
| Kritchevsky, D | 1 |
| Ducobu, J | 1 |
| Calder, D | 1 |
| Canzler, H | 1 |
| Bojanovski, D | 1 |
| Brousseau, T | 1 |
| Lecerf, JM | 1 |
| Luc, G | 1 |
| Devulder, B | 1 |
| Fruchart, JC | 2 |
| Amouyel, P | 1 |
| Kornitzer, M | 1 |
| Dramaix, M | 1 |
| Vandenbroek, MD | 1 |
| Everaert, L | 1 |
| Gerlinger, C | 1 |
| Shepherd, J | 1 |
| Föger, B | 1 |
| Drexel, H | 1 |
| Hopferwieser, T | 1 |
| Miesenböck, G | 1 |
| Ritsch, A | 1 |
| Lechleitner, M | 1 |
| Tröbinger, G | 1 |
| Patsch, JR | 1 |
| Branchi, A | 1 |
| Rovellini, A | 1 |
| Gugliandolo, AG | 1 |
| Chojnowska-Jezierska, J | 1 |
| Jabłoński, S | 1 |
| Tkaczewski, W | 1 |
| Bruckert, E | 1 |
| De Gennes, JL | 1 |
| Malbecq, W | 1 |
| Baigts, F | 1 |
| Steinmetz, A | 1 |
| Schwartz, T | 1 |
| Hehnke, U | 1 |
| Kaffarnik, H | 1 |
| Ceska, R | 1 |
| Sobra, J | 1 |
| Kvasnicka, J | 1 |
| Procházková, R | 1 |
| Kvasilová, M | 1 |
| Haas, T | 1 |
| Farmer, JA | 1 |
| Gotto, AM | 1 |
| Raslová, K | 1 |
| Dubovská, D | 1 |
| Mongiellová, V | 1 |
| Trnovec, T | 1 |
| Wierzbicki, AS | 2 |
| Lumb, PJ | 2 |
| Cheung, J | 1 |
| Crook, MA | 2 |
| Wysocki, J | 2 |
| Szygula, B | 1 |
| Semra, YK | 1 |
| Szyguła, B | 1 |
| Herman, Z | 1 |
| Bergemann, R | 1 |
| Brandt, A | 1 |
| Siegrist, W | 1 |
| Kirchgässler, KU | 1 |
| Schiffner-Rohe, J | 1 |
| Stahlheber, U | 1 |
| Cwalina, L | 1 |
| Lebek, M | 1 |
| Wisniewska-Wanat, M | 1 |
| Morazain, R | 1 |
| Sauvanet, JP | 2 |
| Ol'binskaia, LI | 1 |
| Vartanova, OA | 1 |
| Aleksandrovskaia, TN | 1 |
| Shaldaeva, VV | 1 |
| Schlienger, JL | 1 |
| Boucherle, A | 1 |
| Calop, J | 1 |
| Rossignol, AM | 1 |
| Bost, M | 1 |
| Weisweiler, P | 3 |
| Schwandt, P | 2 |
| Karádi, I | 1 |
| Pados, G | 1 |
| Németh-Csóka, M | 1 |
| Romics, L | 1 |
| Reiner, Z | 1 |
| Salzer, B | 1 |
| Kes, P | 1 |
| Bard, JM | 1 |
| Fievet, C | 1 |
| Kandoussi, A | 1 |
| Slimane, M | 1 |
| Douste-Blazy, P | 1 |
| Bertolini, S | 1 |
| Elicio, N | 1 |
| Daga, A | 1 |
| Degl'Innocenti, ML | 1 |
| Balestreri, R | 1 |
| Fusi, MG | 1 |
| Cotta Ramusino, AM | 1 |
| Carozzi, A | 1 |
| Hunninghake, DB | 1 |
| Peters, JR | 1 |
| Palmer, RH | 2 |
| Knopp, RH | 1 |
| Brown, WV | 2 |
| Dujovne, CA | 1 |
| Farquhar, JW | 1 |
| Feldman, EB | 1 |
| Goldberg, AC | 2 |
| Grundy, SM | 1 |
| Lasser, NL | 1 |
| Mellies, MJ | 1 |
| Schonfeld, G | 1 |
| Anderson, C | 1 |
| Dillingham, MA | 1 |
| Jacotot, B | 1 |
| Beaumont, JL | 1 |
| Beaumont, V | 1 |
| Buxtorf, JC | 1 |
| Edouard, L | 1 |
| Doucet, F | 1 |
| Carcone, B | 1 |
| Merk, W | 1 |
| Jacob, B | 1 |
| Baggio, G | 1 |
| Gasparotto, A | 1 |
| Ciuffetti, G | 1 |
| Valerio, G | 1 |
| Fellin, R | 1 |
| Senin, U | 1 |
| Gabelli, C | 1 |
| Crepaldi, G | 1 |
| Leiss, O | 1 |
| Meyer-Krahmer, K | 1 |
| von Bergmann, K | 1 |
| Genton, P | 1 |
| Foliguet, B | 1 |
| Kolopp, M | 1 |
| Malmendier, CL | 2 |
| Delcroix, C | 2 |
| Lontie, JF | 1 |
| Postiglione, A | 1 |
| Rubba, P | 1 |
| Cicerano, U | 1 |
| Chierchia, I | 1 |
| Mancini, M | 1 |
| Rouffy, J | 1 |
| Chanu, B | 1 |
| Bakir, R | 1 |
| Djian, F | 1 |
| Goy-Loeper, J | 1 |
| Sirtori, M | 1 |
| Gianfranceschi, G | 1 |
| Frosi, T | 1 |
| Montanari, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double-Blind Study Comparing the Efficacy and Safety of 145 mg Fenofibrate, 10 mg Ezetimibe and Their Combination in Patients With Type IIb Dyslipidemia and Features of the Metabolic Syndrome[NCT00349284] | Phase 3 | 181 participants | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for fenofibrate and Apolipoprotein B-100, Familial Defective
| Article | Year |
|---|---|
Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies.
Topics: Adult; Atorvastatin; Azetidines; Blood Component Removal; Cholesterol, LDL; Combined Modality Therap | 2014 |
The fibrates in clinical practice: focus on micronised fenofibrate.
Topics: Adolescent; Adult; Aged; Cholesterol, LDL; Coronary Disease; Drug Compounding; Female; Fenofibrate; | 1994 |
Choosing the right lipid-regulating agent. A guide to selection.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Fenofibrat | 1996 |
Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfib | 1987 |
Effects of fibric acid derivatives on biliary lipid composition.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Feno | 1987 |
25 trials available for fenofibrate and Apolipoprotein B-100, Familial Defective
| Article | Year |
|---|---|
Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter,
Topics: Anticholesteremic Agents; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fem | 2009 |
Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels.
Topics: Adipose Tissue; Animals; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins | 1983 |
[Effect of lipanthyl on parameters of lipid metabolism in patients with primary hyperlipoproteinemia].
Topics: Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Double-Blind Method; Female; Fenofibrate; H | 1984 |
[Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
Topics: Adult; Aged; Bezafibrate; Cholesterol; Clinical Trials as Topic; Female; Fenofibrate; Humans; Hyperl | 1984 |
[Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Female; Fenofibrate; | 1982 |
Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
Topics: Cholesterol; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type II | 1980 |
Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: an open Belgian multicenter study.
Topics: Adolescent; Adult; Aged; Belgium; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Compounding; | 1994 |
Fenofibrate improves postprandial chylomicron clearance in II B hyperlipoproteinemia.
Topics: Adult; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Chylomicrons; Diet | 1994 |
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Fema | 1995 |
Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Female; Fenof | 1996 |
Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Drug Administrati | 1997 |
Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Cholestero | 1997 |
Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb.
Topics: Adult; Arteriosclerosis; Cytokines; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypol | 1998 |
High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Chol | 1998 |
[Levels of tumor necrosis factor alpha in serum of patients with hyperlipoproteinemia IIB before and after micronized fenofibrate therapy].
Topics: Adult; Apolipoproteins B; Arteriosclerosis; Cholesterol; Drug Compounding; Female; Fenofibrate; Huma | 1998 |
Cost effectiveness of micronised fenofibrate and simvastatin in the short-term treatment of type IIa and type IIb hyperlipidaemia.
Topics: Anticholesteremic Agents; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipoproteinemia Typ | 1997 |
Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Fibrin | 2001 |
Low-dose colestipol plus fenofibrate: effects on plasma lipoproteins, lecithin:cholesterol acyltransferase, and postheparin lipases in familial hypercholesterolemia.
Topics: Adolescent; Adult; Apolipoproteins; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Drug Therapy, Co | 1989 |
Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb.
Topics: Adult; Anticholesteremic Agents; Capsules; Clinical Trials as Topic; Drug Administration Schedule; F | 1988 |
Effects of fibric acid derivatives on biliary lipid composition.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Feno | 1987 |
Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipide | 1987 |
Fenofibrate affects the compositions of lipoproteins.
Topics: Adult; Apolipoproteins; Cholesterol; Clinical Trials as Topic; Double-Blind Method; Female; Fenofibr | 1987 |
Effects of several lipid-lowering drugs on skin total and esterified cholesterol.
Topics: Cholesterol Esters; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibric Acids; Humans; Hyp | 1986 |
Pantethine versus fenofibrate in the treatment of type II hyperlipoproteinemia.
Topics: Clinical Trials as Topic; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipoproteinemia Typ | 1985 |
Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B.
Topics: Adult; Apolipoproteins A; Apolipoproteins B; Clofibrate; Clofibric Acid; Drug Evaluation; Female; Fe | 1985 |
43 other studies available for fenofibrate and Apolipoprotein B-100, Familial Defective
| Article | Year |
|---|---|
Efficacy and tolerability of a "suprabioavailable" formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials.
Topics: Adolescent; Adult; Aged; Biological Availability; Cholesterol, HDL; Clinical Trials as Topic; Female | 2002 |
[Pleiotropic effects of micronized fenofibrate in patients with combined hyperlipidemia].
Topics: Adult; Carrier Proteins; Cholesterol, HDL; Cholesterol, LDL; Cytokines; Enzyme-Linked Immunosorbent | 2002 |
Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia.
Topics: Chemokine CCL2; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Humans; Hyperlipoproteinemia | 2003 |
The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease.
Topics: Adult; Antioxidants; Apolipoprotein A-I; Apolipoproteins B; Aryldialkylphosphatase; Body Mass Index; | 2003 |
Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia.
Topics: Adult; Apolipoprotein A-I; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins; Fenofibrate; | 2006 |
The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
Topics: Adult; Aged; Analysis of Variance; Apolipoprotein A-I; Apolipoproteins B; Apolipoproteins E; Atorvas | 2006 |
Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.
Topics: Anticholesteremic Agents; Cell Line, Tumor; Clofibric Acid; DNA-Binding Proteins; Fenofibrate; Furin | 2008 |
Fenofibrate therapy of hypertriglyceridaemia. Differential effects on LDL cholesterol level in type IV and in type IIb primary hyperlipoproteinaemia.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperl | 1984 |
Long-term effects of fenofibrate on serum lipids and on lipoprotein cholesterol in type II hyperlipoproteinemic patients.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Fenofibrate | 1984 |
Effect of procetofen on serum lipids and apoproteins.
Topics: Adult; Apoproteins; Cholesterol; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Lipids; | 1984 |
Application of the concanavalin A precipitation technique in an evaluation of fenofibrate action on cholesterolemia in IIa and IIb hyperlipemic subjects.
Topics: Adult; Aged; Aging; Anticholesteremic Agents; Chemical Precipitation; Cholesterol; Concanavalin A; F | 1983 |
Fenofibrate and human liver. Lack of proliferation of peroxisomes.
Topics: Adult; Aged; Cell Division; Diet; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperli | 1983 |
Fenofibrate and cholestyramine in type II hyperlipoproteinaemia.
Topics: Adult; Aspartate Aminotransferases; Cholesterol; Cholestyramine Resin; Fenofibrate; Humans; Hyperlip | 1982 |
[One year fenofibrate treatment of type II primary hyperlipidaemia. Effects on lipoproteins and biological tolerance (author's transl)].
Topics: Adolescent; Adult; Aged; Alkaline Phosphatase; Cholesterol; Dietary Fats; Female; Fenofibrate; Human | 1980 |
[Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)].
Topics: Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Cholesterol; Female; Fenofibrate; Humans; Hyp | 1980 |
[Influence of fenofibrate on blood platelet functions (author's transl)].
Topics: Blood Coagulation; Cholesterol; Dietary Fats; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyp | 1980 |
[Pharmacology of fenofibrate (author's transl)].
Topics: Animals; Cholesterol; Clofibrate; Dogs; Dose-Response Relationship, Drug; Fenofibrate; Humans; Hyper | 1980 |
[Effect of phenofibrate on the blood serum lipid level in hyperlipoproteinemias and its comparison with clofibrate].
Topics: Adult; Aged; Cholesterol; Clofibrate; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyp | 1980 |
[Clinical study of fenofibrate in hyperlipoproteinemias].
Topics: Adult; Aged; Cholesterol; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoprotei | 1980 |
The effect of etofibrate retard, bezafibrate and procetofen.
Topics: Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipopr | 1980 |
[Detection of the Arg 3500-->Gln mutation of B apolipoprotein. Value in clinical practice].
Topics: Adult; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Cholesterol; Cholesterol, | 1995 |
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibr | 1993 |
[Clinical effectiveness of acipimox and fenofibrate in patients with hyperlipoproteinemia type II].
Topics: Adult; Aged; Cholesterol; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic A | 1993 |
[The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia].
Topics: Adult; Aged; Female; Fenofibrate; Fibrinogen; Heterozygote; Humans; Hyperlipidemia, Familial Combine | 1996 |
Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson).
Topics: Bezafibrate; Cost-Benefit Analysis; Diabetes Complications; Fenofibrate; Gemfibrozil; Humans; Hyperl | 1993 |
Influence of a hypolipemic drug (procetofene) on platelet functions and lipid composition in type II B hyperlipoproteinemia.
Topics: Adenosine Diphosphate; Adult; Blood Coagulation; Cholesterol; Epinephrine; Fenofibrate; Humans; Hype | 1979 |
Treatment of hyperlipoproteinemia (HLP) type II A with a new phenoxy-isobuturic acid derivative, procetofen.
Topics: Adult; Aged; Apolipoproteins; Body Weight; Cholesterol; Female; Fenofibrate; Humans; Hyperlipoprotei | 1979 |
[Effect of procetofen on the lipoprotein profile in patients with type II hyperlipoproteinemia].
Topics: Adult; Aged; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Male; Middle A | 1979 |
[The clinico-biochemical activity and tolerance of the hypolipidemic preparation lipanthyl].
Topics: Arteriosclerosis; Drug Evaluation; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperl | 1991 |
[Evaluation of the addition of fenofibrate to the simvastatin-cholestyramine combination].
Topics: Anticholesteremic Agents; Cholestyramine Resin; Drug Therapy, Combination; Fenofibrate; Humans; Hype | 1991 |
[Treatment of essential hypercholesterolemia by normolipidemic drugs in children].
Topics: Adolescent; Child; Child, Preschool; Cholestyramine Resin; Clofibrate; Fenofibrate; Humans; Hydroxym | 1989 |
Colestipol plus fenofibrate versus synvinolin in familial hypercholesterolaemia.
Topics: Adult; Cholesterol, LDL; Colestipol; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipoprotei | 1986 |
[The effect of lipanthyl therapy on hyperlipoproteinemia type II/a, II/b and IV].
Topics: Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Propionates | 1988 |
[Comparison of the effects of fenofibrate administered in doses of 3 x 100mg and 1 x 250mg per day in patients with type IIA, IIB and IV hyperlipoproteinemias].
Topics: Adult; Aged; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV | 1988 |
Effect of fenofibrate on apolipoprotein B containing lipoprotein particles.
Topics: Apolipoproteins B; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; H | 1988 |
Potential use of fenofibrate and other fibric acid derivatives in the clinic.
Topics: Clofibrate; Fenofibrate; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hy | 1987 |
Fenofibrate and colestipol: effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolaemia.
Topics: Adult; Apolipoproteins; Body Weight; Cholesterol; Cholesterol, HDL; Colestipol; Female; Fenofibrate; | 1986 |
Long term-effect of fenofibrate on lipoprotein level and composition in different types of genetic hyperlipidemias.
Topics: Cholesterol; Cholesterol, LDL; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipop | 1986 |
Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate.
Topics: Adult; Bezafibrate; Bile; Bile Acids and Salts; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fem | 1986 |
Morphometric study of human hepatic cell modifications induced by fenofibrate.
Topics: Adult; Aged; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type V; | 1987 |
The effect of combined fenofibrate and cholestyramine therapy on low-density lipoprotein kinetics in familial hypercholesterolemia patients.
Topics: Adult; Apolipoproteins; Cholestyramine Resin; Drug Therapy, Combination; Female; Fenofibrate; Humans | 1987 |
Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins B; Female; Fenofibrate; Humans; Hyperl | 1985 |
Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.
Topics: Adult; Aged; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins C; Cholesterol, HDL; Cholest | 1985 |